Artificial Pancreas System Market Size, Share & Trends Analysis Report By Type (Threshold Suspended Device System, Control to Range (CTR) System, Control to Target (CTT) System), By End User (Hospitals, Ambulatory Surgical Centers (ASCs), Clinics, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Artificial Pancreas System Market Size

The global artificial pancreas system market size was valued at USD 442.3 million in 2025 and is projected to grow from USD 481.22 million in 2026 to USD 944.88 million by 2034, registering a CAGR of 8.8% during the forecast period from 2026 to 2034. North America dominated the artificial pancreas system market with a market share of 42.6% in 2025.

An artificial pancreas system is an advanced medical technology designed to automatically regulate blood glucose for people with diabetes, mainly Type 1 diabetes. An artificial pancreas system brings together continuous glucose monitoring technology with an insulin-delivery device such as an insulin pump controlled by advanced algorithms, re-creating the glucose-regulatory function of a healthy pancreas.

The global Artificial Pancreas Systems (APS) market is expected to grow from an upsurge in the prevalence of diabetes, technological advancements, and growing awareness about the management of diabetes. The integration of advanced technologies such as continuous glucose monitoring and insulin pumps, which offer better glucose control for patients has significantly improved the functionality of artificial pancreas systems. Additionally, there is a growing adoption of digital health solutions together with artificial intelligence-driven algorithms in artificial pancreas systems, facilitating more precise and personalized management of diabetes.

Type Insights

The market is divided into threshold suspended device system, control to range (CTR) system and control to target (CTT) system. The threshold suspended device system segment dominates the global market for artificial pancreas systems, as it plays an essential role in preventing hypoglycemia the most critical concern of people with diabetes. These systems automatically suspend the flow of insulin when glucose levels reach or drop below a predefined threshold, thereby minimizing the risk of extreme low-blood-sugar levels. For example, MiniMed 530G with SmartGuard technology, manufactured by Medtronic, has significantly been in use due to its effectiveness in reducing the frequency of hypoglycemia occurrences. This, when coupled with its relative ease of use and proven safety, has ensured a speedy increase in patient and clinician acceptance and will continue to propel its growth in the market.

Request Customizationto receive a tailored report.

End Users Insights

The market is hospitals, ambulatory surgical centers (ASCs), clinics and others. The hospitals are estimated to own the market, due to their role as primary centers for advanced diabetes management and treatment. The necessary infrastructure and expertise available at hospitals ensure the handling of complex cases, provision of comprehensive patient education, and device calibration and monitoring. Further, they often lead clinical trials and pilot programs, thus strongly propagating adoption and trust in artificial pancreas systems technology within the healthcare community, in the process consolidating the market power of hospitals.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America is the most significant global artificial pancreas system market shareholder and is expected to expand substantially during the forecast period. North America has a high population, and diabetes prevalence, especially Type 1 diabetes. The Centers for Disease Control and Prevention indicate that in the United States, over 34 million people have diabetes, with around 1.6 million having Type 1 diabetes. This serious health burden in the country results in a high market need for advanced solutions for diabetes management, an artificial pancreas system being one of them. The region also houses many companies for medical devices and is a center for research institutions that contribute to an environment fit for further innovation and technological advancement in artificial pancreas systems.

The United States artificial pancreas system market is leading in terms of market share. A strong presence of leading medical device manufacturers and research institutions in the United States is further fostering innovation in the country and propelling the growth of advanced diabetes management technologies. For example, the FDA approved the MiniMed 670G system by Medtronic as the first commercially available hybrid closed-loop insulin delivery system. The approval of this product has led to further product advancements and an increase in the adoption of the artificial pancreas system. Secondly, the conducive reimbursement policies and insurance coverage for devices and diabetes-related services in the United States further incentivize patient adoption of the artificial pancreas system, thereby increasing the market.

The Canadian artificial pancreas system market is poised to grow significant prevalence of diabetes, with approximately 11 million people living with diabetes or prediabetes, according to Diabetes Canada. Moreover, Canada has a vigorous tradition of research in medicine and innovation; several research institutions and healthcare centers in the country are actively engaging in diabetes research and clinical trials. For instance, the University of Alberta in Canada conducted groundbreaking research on the first successful clinical trial of an artificial pancreas system using the Diabeloop DBLG1 system. This research further contributes to the advancement of the artificial pancreas system field and encourages its market growth by validating the effectiveness of these technologies.

These factors are estimated to drive the North American artificial pancreas system market growth.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia-Pacific Artificial Pancreas System Market Trends

Asia-Pacific region is a pivotal market for the artificial pancreas system industry, significant number of individuals with diabetes. According to the International Diabetes Federation, the Asia-Pacific region harbors around 60% of the world's diabetic population. The prevalence of diabetes is soaring in countries such as China, India, and Japan, where lifestyle alterations, urbanization, and an aging population are contributing to this fast-increasing burden of the disease. Therefore, a significant market demand for advanced diabetes management solutions like artificial pancreas systems exists to address the diverse needs of patients in the region.

China's artificial pancreas system market has a major role in shaping the dynamics of the In China, apart from high diabetes prevalence, the country's rapid process of urbanization and aging population become the most important driving force for the artificial pancreas system industry. Urbanization is associated with changes in the mode of life, among which are activities such as sedentary behavior and unhealthy dietary habits, which may increase the risk of diabetes. Besides high diabetes prevalence, the rapidly aging population in China adds to the diabetes burden since older adults are susceptible to diabetes-related complications.

Indian artificial pancreas systems and digital health ecosystem is rapidly evolving, with the widespread adoption of smartphones and internet connectivity. This digital transformation provides an opportunity for the adoption of telehealth solutions and remote monitoring platforms, in turn incorporating artificial pancreas systems for the management of diabetes. Moreover, India's government initiatives, such as the NPCDCS (National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke), focus on promoting preventive healthcare and improving access to diabetes care services.

Thus, the factors above are estimated to boost the Asia-Pacific artificial pancreas system market growth.

List of Key and Emerging Players in Artificial Pancreas System Market